PaulRiskaMD
Infectious Disease • Bronx, NYHIV/AIDS Medicine
Associate Professor of Clinical Medicine, Infectious Diseases, Albert Einstein College of Medicine
Dr. Riska is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
111 E 210th St
Bronx, NY 10467Phone+1 718-920-6494Fax+1 718-231-9187
Summary
- Paul Riska, MD is a healthcare provider based in Bronx, NY, specializing in infectious disease with a subspecialty in HIV/AIDS medicine. He educated at Duke University School of Medicine and later completed his residency in internal medicine at New York Presbyterian Hospital and fellowship in infectious disease at Montefiore Medical Center/Albert Einstein College of Medicine. Dr. Riska has made notable contributions to his field through multiple publications and involvement in various clinical trials, particularly focusing on the treatment of infectious diseases like influenza and HIV, as well as antibiotic-resistant infections such as methicillin-resistant Staphylococcus aureus bloodstream infections and C. Difficile.
Education & Training
Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Fellowship, Infectious Disease, 1992 - 1998
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1989 - 1992
Duke University School of MedicineClass of 1989
Certifications & Licensure
NY State Medical License 1990 - 2026- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Infectious Disease
Clinical Trials
- Respiratory Virus Hospitalization Study (FLU 003 Plus) Start of enrollment: 2009 Aug 01
Roles: Principal Investigator, Contact
- Treatment Algorithm to Reduce the Use of Vancomycin in Adults With Blood Stream Infection Start of enrollment: 2011 Feb 01
- Bezlotoxumab as Secondary Prophylaxis for C. Difficile in High-risk Hospitalized Patients Exposed to Antibiotics. Start of enrollment: 2019 Aug 30
Publications & Presentations
PubMed
- 37 citationsEmergence of resistance to rifampin and rifalazil in Chlamydophila pneumoniae and Chlamydia trachomatis.Andrei Kutlin, Stephan Kohlhoff, Patricia M. Roblin, Margaret R. Hammerschlag, Paul F. Riska
Antimicrobial Agents and Chemotherapy. 2005-03-01 - 47 citationsEffect of Algorithm-Based Therapy vs Usual Care on Clinical Success and Serious Adverse Events in Patients with Staphylococcal Bacteremia: A Randomized Clinical TrialThomas L. Holland, Issam I Raad, Helen W. Boucher, Deverick J. Anderson, Sara E. Cosgrove
JAMA. 2018-09-25 - 8 citationsAnorectal Testing for Mpox Virus Infection in Men Who Have Sex With Men With and Without Proctitis.Eric A Meyerowitz, Inessa Gendlina, Vimi J Desai, Robert Grossberg, Singh R Nair
Clinical Infectious Diseases. 2023-03-04
Journal Articles
- Effect of Algorithm-Based Therapy vs Usual Care on Clinical Success and Serious Adverse Events in Patients with Staphylococcal BacteremiaIssam Raad, Mark E Rupp, Thomas L Holland, Helen W Boucher, G Ralph Corey, Paul Riska, Deverick J Anderson, Matthew Sims, Dannah Wray, Sara E Cosgrove, Manuela Carugat..., JAMA
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
